This year, blood tests have moved to the forefront of preventive medicine with two breakthroughs that capture both imagination and caution: on one side, “multi-cancer” tests capable of detecting early signs of dozens of tumors from a single sample; on the other, new Alzheimer’s tests that measure brain-related proteins directly in plasma. Their promise is powerful — diagnose earlier, treat better, and reduce the long, exhausting path of costly or invasive examinations.
Yet experts warn that enthusiasm should not turn into indiscriminate use. In cancer, these tests still coexist with the uncertainty of false positives and negatives, the risk of overdiagnosis — findings that would never have caused harm — and the cascade of follow-up procedures such as imaging, biopsies, and surgeries that can generate anxiety, side effects, and unnecessary expenses if not guided by clear protocols.
They are not meant to replace classic screening tools like mammograms or colonoscopies but rather to complement them when properly indicated and validated. In Alzheimer’s, the temptation to “find out” with a simple blood draw is understandable but dangerous. A result outside its clinical context neither confirms nor rules out the disease; it can be influenced by other conditions, and without a neurological evaluation, a detailed history, cognitive testing, and, when appropriate, confirmatory procedures, the label of “positive” may do more harm than good.
Hence the central message is both prudent and direct: taking an Alzheimer’s blood test as a routine checkup during a general practitioner visit is not a good idea. If there are symptoms of memory loss, disorientation, or behavioral changes, the right path is referral to a specialist, pre- and post-test counseling, and shared decision-making. What comes next is delicate work: establishing clear guidelines on who should be tested, when, and how; building follow-up circuits that prevent defensive medicine; maintaining honest communication about uncertainty and limitations; and ensuring fair access so that these innovations do not become tools only for those who can afford them.
The goal is ambitious but achievable — for the “blood diagnosis revolution” to arrive as real and responsible progress, not as a trend that promises more than science can yet deliver.
